Skip to content

US · GNTA · BIOTECHNOLOGY

Genenta Science S.p.A. (GNTA) intrinsic value and stock valuation

$0.99as of 2026-11-21 · Mkt cap 25.46M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Genenta Science S.p.A. DCF and intrinsic value

InvestorsCraft values GNTA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GNTA’s statements →

Genenta Science S.p.A. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Milan, MI 20132 genenta.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-6.27M
20192025
Free cash flow
-$-6.88M
20192025
Total equity
$21.8M+7.6% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-6.34M-$-10.2M-$-11.53M-$-10.79M-$-5.93M
Net income-$-6.27M-$-9.31M-$-11.44M-$-8.28M-$-5.76M
EPSd-$-318.11K-$-509.58K-$-627.88K-$-454.45K-$-316.14K
Operating cash flow-$-6.87M-$-6.24M-$-11.21M-$-7.42M-$-6.96M
Capital expenditure-$-10K-$0.00-$-10K-$-30K-$-10K
Free cash flow-$-6.88M-$-6.24M-$-11.22M-$-7.45M-$-6.97M
Total assets$31.9M$14.8M$22.4M$33.4M$40M
Total debt$7.6M$10K$0.00$0.00$0.00
Net debt$2.08M-$-4.57M-$-3.69M-$-29.79M-$-37.24M
Total equity$21.8M$12.5M$20.4M$31.1M$38.9M
Cash and short-term investments$28.2M$12.7M$18.8M$29.8M$37.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$30K$50K$40K$10K$10K
Gross profit-$-30K-$-50K-$-40K-$-10K-$-10K
Research and development expenses$2.59M$5.03M$6.36M$5.21M$3.53M
Selling, general and administrative expenses$3.72M$5.13M$5.12M$5.57M$2.39M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$6.32M$10.2M$11.5M$10.8M$5.92M
Cost and expenses$6.34M$10.2M$11.5M$10.8M$5.93M
Interest income$970K$0.00$0.00$0.00$0.00
Interest expense$380K$0.00$0.00$0.00$0.00
Depreciation and amortization$30K$50K$40K$10K$10K
Ebitda-$-5.86M-$-9.26M-$-11.4M-$-8.27M-$-5.76M
Operating income-$-6.34M-$-10.2M-$-11.53M-$-10.79M-$-5.93M
Total other income/expenses, net$70K$890K$90K$2.51M$160K
Income before tax-$-6.27M-$-9.31M-$-11.44M-$-8.28M-$-5.76M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-6.27M-$-9.31M-$-11.44M-$-8.28M-$-5.76M
Weighted average shares outstanding$19.7M$18.3M$18.2M$18.2M$18.2M
Weighted average diluted shares outstanding$19.7M$18.3M$18.2M$18.2M$18.2M
Balance sheet
20252024202320222021
Cash and short-term investments$28.2M$12.7M$18.8M$29.8M$37.2M
Net receivables$1.29M$1.45M$2M$1.56M$1.42M
Inventory$0.00$0.00$0.00$140K$80K
Total current assets$30M$14.5M$21.3M$31.7M$38.8M
Property, plant and equipment, net$20K$40K$60K$110K$20K
Goodwill and intangible assets$0.00$90K$50K$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.91M$350K$1.09M$1.72M$1.27M
Total assets$31.9M$14.8M$22.4M$33.4M$40M
Accounts payable$1.51M$320K$290K$1.19M$190K
Short-term debt$0.00$10K$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.12M$2.1M$1.74M$2.18M$1.14M
Long-term debt$7.6M$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$7.93M$230K$180K$120K$30K
Capital lease obligations$0.00$10K$0.00$0.00$0.00
Total liabilities$10.1M$2.33M$1.91M$2.3M$1.17M
Common stock$84.3M$68.5M$67.3M$66.6M$65.9M
Retained earnings-$-62.59M-$-56.06M-$-47.14M-$-35.47M-$-27.02M
Accumulated other comprehensive income (loss)$170K$90K$230K$0.00$0.00
Total equity$21.8M$12.5M$20.4M$31.1M$38.9M
Total investments$22.6M$8.08M$15.1M$0.00$0.00
Total debt$7.6M$10K$0.00$0.00$0.00
Net debt$2.08M-$-4.57M-$-3.69M-$-29.79M-$-37.24M
Cash flow statement
20252024202320222021
Net income-$-6.53M-$-8.91M-$-11.65M-$-8.48M-$-5.53M
Depreciation and amortization$30K$40K$40K$10K$0.00
Stock-based compensation$1.01M$850K$740K$720K$500K
Change in working capital-$-1.58M$1.72M-$-420K$240K-$-1.94M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.31M$30K-$-730K$1M-$-370K
Net cash provided by operating activities-$-6.87M-$-6.24M-$-11.21M-$-7.42M-$-6.96M
Investments in property, plant and equipment-$-10K-$0.00-$-10K-$-30K-$-10K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-14.54M$6.88M-$-14.89M-$-30K-$-10K
Common stock issued$0.00$0.00$0.00$0.00$28.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$22.3M$270K$0.00$0.00$28.7M
Net change in cash$950K$890K-$-26.1M-$-7.45M$21.8M
Cash at end of period$5.53M$4.58M$3.69M$29.8M$37.2M
Operating cash flow-$-6.87M-$-6.24M-$-11.21M-$-7.42M-$-6.96M
Capital expenditure-$-10K-$0.00-$-10K-$-30K-$-10K
Free cash flow-$-6.88M-$-6.24M-$-11.22M-$-7.45M-$-6.97M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Genenta Science S.p.A.

        Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.

        CEO
        Pierluigi Paracchi
        Employees
        9
        Beta
        0.75

        Explore

        Frequently asked questions

        What is the intrinsic value of Genenta Science S.p.A. (GNTA)?

        InvestorsCraft does not currently publish an intrinsic value for GNTA. How the IC value is calculated.

        Is GNTA undervalued?

        InvestorsCraft does not publish an undervaluation signal for GNTA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.